Zusammenfassung
Die perkutane Strahlentherapie ist eine wirksame Maßnahme zur Reduktion der lokalen inflammatorischen Reaktion sowie zur Inaktivierung proliferativer Eigenschaften des Tumors. Daher verfügt sie über eine messbare Effektivität bei Schmerzen, die durch Knochenmetastasen hervorgerufen werden. Knochenmetastasen entstehen durch hämatogene Tumorzelldissemination in das Knochenmark und sind eigentlich Metastasen des Knochenmarks. Die dort wachsenden Tumorzellen können die Skelett- und Kalziumhomöostase stören und sekundäre Knochenveränderungen hervorrufen, die als Tumorosteopathien bezeichnet werden.
Similar content being viewed by others
Literatur
Adamietz IA, Diel IJ (2003) Bisphosphonate. Onkologe 9:495–509
Algur E, Macklis RM, Hafeli UO (2005) Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines. Int J Radiat Oncol Biol Phys 61:535–542
Arcangeli G, Giovinazzo G, Saracino B et al (1998) Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration. Int J Radiat Oncol Biol Phys 42:1119–1126
Blitzer PH (1985) Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer 55:1468–1472
Blum RH, Novetsky D, Shasha D et al (2003) The multidisciplinary approach to bone metastases. Oncology (Williston Park) 17:845–857; discussion 862–843, 867
Bone-Trial-Working-Party (1999) 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party. Radiother Oncol 52:111–121
Böttcher HD, Adamietz IA (1997) Klinik der Skelettmetastasen. Zuckschwerdt, München/Bern/Wien/New York
Chow E, Zeng L, Salvo N et al (2012) Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol) 24:112–124
Coleman RE, Gnant M (2009) New results from the use of bisphosphonates in cancer patients. Curr Opin Support Palliat Care 3:213–218
Dempster DW, Lambing CL, Kostenuik PJ et al (2012) Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Clin Ther 34:521–536
Enright K, Clemons M, Chow E (2004) Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates-Toronto Sunnybrook Regional Cancer Centre experience. Support Care Cancer 12:48–52
Expert Panel on Radiation Oncology-Bone Metastases, Lutz ST, Lo SS et al (2012) Appropriateness Criteria® non-spine bone metastases. J Palliat Med 15:521–526
Gnant M (2009) Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials. Curr Cancer Drug Targets 9:824–883
Habl G, Straube C, Schiller K, Duma MN et al (2017) Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). BMC Cancer 17:361–371. https://doi.org/10.1186/s12885-017-3341-2
Henry DH, Costa L, Goldwasser F et al (2001) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125–1132
Hoskin PJ (2003) Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev 29:321–327
Huisman M, van den Bosch MA, Wijlemans JW et al (2012) Effectiveness of reirradiation for painful bone metastases: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 84:8–14
Johnstone C, Lutz ST (2014) External beam radiotherapy and bone metastases. Ann Palliat Med 3:114–122. https://doi.org/10.3978/j.issn.2224-5820.2014.04.06
Kagan AR, Rose CM, Bedwinek JM et al (2000) Bone metastases. American College of Radiology. ACR appropriateness criteria. Radiology 215:1077–1104
Kijima T, Fujii Y, Suyama T et al (2009) Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int 103:620–624
Kimura T (2018) Multidisciplinary approach for bone metastasis: a review. Cancer 10:156–165. https://doi.org/10.3390/cancers10060156
Koswig S, Budach V (1999) Remineralisation und Schmerzlinderung von Knochenmetastasen nach unterschiedlich fraktionierter Strahlentherapie (10mal 3 Gy vs. 1mal 8 Gy). Strahlenther Onkol 175:500–508
Koswig S, Buchali A, Bohmer D et al (1999) Palliative Strahlentherapie von Knochenmetastasen. Eine retrospektive Analyse von 176 Patienten. Strahlenther Onkol 175:509–514
Lutz S, Berk L, Chang E et al (2011) Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 79:965–976
Macedo F, Ladeira K, Pinho F, Saraiva N et al (2017) Bone metastases: an overview. Oncol Rev 11:321–327
Mercadante S (2006) Scoring the effect of radiotherapy for painful bone metastases. Support Care Cancer 14:967–969
Mercadante S, Fulfaro F (2007) Management of painful bone metastases. Curr Opin Oncol 19:308–314
Rieden K, Adolph J, Lellig U et al (1989a) Strahlentherapeutischer Effekt bei knochenmetastasen in Abhängigkeit von der Metastasenhäufig, Metastasenlokalisation und der Histologie des Primärtumors. Strahlenther Onkol 165:380–385
Rieden K, Mende U, Adolph J et al (1989b) Akzelerierte Bestrahlung von Knochenmetastasen. Strahlenther Onkol 165:23–27
Saad F (2006) Bone-directed treatments for prostate cancer. Hematol Oncol Clin North Am 20:947–963
Saad F (2008) New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat Rev 34:183–192
Saad F, Abrahamsson PA, Miller K (2009) Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates. BJU Int 104:1573–1579
Salazar OM, DaMotta NW, Bridgman SM et al (1996) Fractionated half-body irradiation for pain palliation in widely metastatic cancers: comparison with single dose. Int J Radiat Oncol Biol Phys 36:49–60
Salazar OM, Sandhu T, da Motta NW et al (2001) Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized Phase III trial of the International Atomic Energy Agency (IAEA). Int J Radiat Oncol Biol Phys 50:765–775
Sauer N, Leising D, Wild B et al (2006) Der Einfluss palliativer Strahlentherapie auf Schmerz und Lebensqualitat bei Patienten mit Knochenmetastasen. Strahlenther Onkol 182:550–556
Souchon R, Wenz F, Sedlmayer F et al (2009) DEGRO practice guidelines for palliative radiotherapy of metastatic breast cancer: bone metastases and metastatic spinal cord compression (MSCC). Strahlenther Onkol 185:417–424
Sprave T, Hees K, Bruckner T et al (2018) The influence of fractionated radiotherapy on the stability of spinal bone metastases: a retrospective analysis from 1047 cases. Radiat Oncol 13:134–142. https://doi.org/10.1186/s13014-018-1082-2
Stopeck AT, Lipton A, Body JJ et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blinded study. J Clin Oncol 28:5132–5239
Tong D, Gillick L, Hendrickson FR (1982) The palliation of symptomatic osseous metastases: final results of the study by the radiation therapy oncology group. Cancer 50:893–899
Tsuya A, Kurata T, Tamura K et al (2007) Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 57:229–232
Ural AU, Avcu F, Candir M et al (2006) In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells. Breast Cancer Res 8:R52
Wu JS, Wong R, Johnston M et al (2003) Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 55:594–605
Wu JS, Monk G, Clark T et al (2006) Palliative radiotherapy improves pain and reduces functional interference in patients with painful bone metastases: a quality assurance study. Clin Oncol (R Coll Radiol) 18:539–544
Yu HH, Hoffe SE (2012) Beyond the conventional role of external-beam radiation therapy for skeletal metastases: new technologies and stereotactic directions. Cancer Control 19:129–136
Zeng L, Lutz S, Chow E et al (2012) Recent important developments in the management of nonspine bone metastases. Curr Opin Support Palliat Care 6:80–84
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this entry
Cite this entry
Adamietz, I.A., Schmidberger, H. (2019). Strahlentherapeutische Behandlung von Knochenmetastasen bei Tumorschmerzen. In: Baron, R., Koppert, W., Strumpf, M., Willweber-Strumpf, A. (eds) Praktische Schmerzmedizin. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54670-9_17-2
Download citation
DOI: https://doi.org/10.1007/978-3-642-54670-9_17-2
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-54670-9
Online ISBN: 978-3-642-54670-9
eBook Packages: Springer Referenz Medizin
Publish with us
Chapter history
-
Latest
Strahlentherapeutische Behandlung von Knochenmetastasen bei Tumorschmerzen- Published:
- 07 November 2018
DOI: https://doi.org/10.1007/978-3-642-54670-9_17-2
-
Original
Schmerztherapie von Skelettmetastasen mittels ionisierender Strahlung- Published:
- 24 November 2014
DOI: https://doi.org/10.1007/978-3-642-54670-9_17-1